Suchen
IDEAYA Biosciences Inc
IDYAZur Watchlist hinzufügen
28.210USD
-0.630-2.18%
Handelsschluss 05/15, 16:00（ET）Kurse um 15 Minuten verzögert
2.48BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über IDEAYA Biosciences Inc Unternehmen
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
IDEAYA Biosciences Inc Informationen
BörsenkürzelIDYA
Name des UnternehmensIDEAYA Biosciences Inc
IPO-datumMay 23, 2019
CEOHata (Yujiro S)
Anzahl der mitarbeiter131
WertpapierartOrdinary Share
GeschäftsjahresendeMay 23
Addresse7000 Shoreline Ct, Suite 350
StadtSOUTH SAN FRANCISCO
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94080
Telefon16504436209
Websitehttps://www.ideayabio.com/
BörsenkürzelIDYA
IPO-datumMay 23, 2019
CEOHata (Yujiro S)
Führungskräfte von IDEAYA Biosciences Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Joshua Bleharski, Ph.D.
Dr. Joshua Bleharski, Ph.D.
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Andres Ruiz Briseno, CPA
Mr. Andres Ruiz Briseno, CPA
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Mr. Scott W. Morrison, CPA
Mr. Scott W. Morrison, CPA
Independent Director
Independent Director
--
--
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Independent Director
Independent Director
--
--
Dr. M. Garret Hampton, Ph.D.
Dr. M. Garret Hampton, Ph.D.
Independent Director
Independent Director
--
--
Dr. Catherine J. Mackey, Ph.D.
Dr. Catherine J. Mackey, Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael A. White, Ph.D.
Dr. Michael A. White, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Joshua Bleharski, Ph.D.
Dr. Joshua Bleharski, Ph.D.
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Andres Ruiz Briseno, CPA
Mr. Andres Ruiz Briseno, CPA
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Mr. Scott W. Morrison, CPA
Mr. Scott W. Morrison, CPA
Independent Director
Independent Director
--
--
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Umsatzaufteilung
FY2025
FY2024
FY2024Q4
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach RegionUSD
Name
Umsatz
Anteil
United States
218.71M
0.00%
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sun, May 10
Aktualisiert: Sun, May 10
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
14.97%
Janus Henderson Investors
8.18%
BlackRock Institutional Trust Company, N.A.
7.45%
Capital Research Global Investors
6.01%
State Street Investment Management (US)
4.71%
Andere
58.69%
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
14.97%
Janus Henderson Investors
8.18%
BlackRock Institutional Trust Company, N.A.
7.45%
Capital Research Global Investors
6.01%
State Street Investment Management (US)
4.71%
Andere
58.69%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
49.16%
Investment Advisor/Hedge Fund
34.40%
Hedge Fund
18.19%
Venture Capital
4.64%
Research Firm
3.40%
Corporation
1.52%
Individual Investor
0.89%
Pension Fund
0.86%
Bank and Trust
0.43%
Institutionelle Beteiligung
Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
518
97.55M
111.03%
-12.93M
2025Q4
494
96.98M
110.62%
-16.62M
2025Q3
460
105.73M
120.62%
-11.57M
2025Q2
449
101.70M
116.06%
-6.32M
2025Q1
454
97.81M
111.68%
-11.15M
2024Q4
442
95.26M
108.96%
-7.87M
2024Q3
426
95.20M
112.79%
+2.56M
2024Q2
409
85.26M
112.59%
-3.91M
2024Q1
388
81.45M
108.91%
-1.44M
2023Q4
351
68.31M
105.94%
-512.62K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Fidelity Management & Research Company LLC
13.15M
14.97%
+3.42K
+0.03%
Dec 31, 2025
Janus Henderson Investors
7.19M
8.18%
+758.12K
+11.79%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
6.54M
7.45%
+208.10K
+3.28%
Dec 31, 2025
Capital Research Global Investors
5.28M
6.01%
-1.27M
-19.43%
Dec 31, 2025
State Street Investment Management (US)
4.13M
4.71%
+893.71K
+27.58%
Dec 31, 2025
Baker Bros. Advisors LP
3.62M
4.12%
+343.38K
+10.48%
Dec 31, 2025
Logos Global Management LP
3.13M
3.56%
+875.00K
+38.89%
Dec 31, 2025
Federated Hermes Global Investment Management Corp.
3.40M
3.87%
-1.23M
-26.59%
Dec 31, 2025
Adage Capital Management, L.P.
2.80M
3.19%
-100.09K
-3.45%
Dec 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Tema Oncology ETF
3.49%
ALPS Medical Breakthroughs ETF
1.16%
Virtus LifeSci Biotech Clinical Trials ETF
0.97%
Invesco Dorsey Wright Healthcare Momentum ETF
0.83%
State Street SPDR S&P Biotech ETF
0.72%
First Trust Innovation Leaders ETF
0.7%
Direxion Daily S&P Biotech Bull 3X Shares
0.45%
ProShares Ultra Nasdaq Biotechnology
0.38%
Avantis US Small Cap Equity ETF
0.29%
Invesco Nasdaq Biotechnology ETF
0.27%
Mehr Anzeigen
Tema Oncology ETF
Anteil3.49%
ALPS Medical Breakthroughs ETF
Anteil1.16%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.97%
Invesco Dorsey Wright Healthcare Momentum ETF
Anteil0.83%
State Street SPDR S&P Biotech ETF
Anteil0.72%
First Trust Innovation Leaders ETF
Anteil0.7%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.45%
ProShares Ultra Nasdaq Biotechnology
Anteil0.38%
Avantis US Small Cap Equity ETF
Anteil0.29%
Invesco Nasdaq Biotechnology ETF
Anteil0.27%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
